HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Supplement AER System Nets $1.5 Mil. Under Ag Approps

This article was originally published in The Tan Sheet

Executive Summary

FDA's dietary supplement adverse event monitoring system will receive $1.5 mil. in funding for FY 2002 under the 1agriculture appropriations conference report adopted by both the House and Senate

You may also be interested in...



FDA Dietary Supplement Claims Oversight Will Be “More Aggressive” – Troy

FDA plans to intensify enforcement of inappropriate structure/function claims, Chief Counsel Daniel Troy asserted at the Food & Drug Law Institute educational conference April 16-17

LipoKinetix Cases Prompt Support For Mandatory Supplement AE Reporting

Seven hepatotoxicity adverse event reports linked to Syntrax' LipoKinetix weight-loss supplement further support the need for mandatory AE reporting for supplement manufacturers, University of Pennsylvania researchers say

FDA appropriations

President Bush approves agriculture appropriations bill Nov. 28; public law 107-76 provides FDA with $1.35 bil. in FY 2002, designates $1.5 mil. for CFSAN to revamp its dietary supplement adverse event monitoring system (1"The Tan Sheet" Nov. 19, p. 13). Labor/HHS approps bill still awaits conference...

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131536

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel